Purpose: To compare bromfenac sodium 0.1%, fluorometholone 0.1% and dexamethasone 0.1% for the control of postoperative inflammation and prevention of cystoid macular edema (CME) after phacoemulsification. Methods: Patients were randomized to receive bromfenac sodium 0.1% for 1 month (OBS1) or 2 months (OBS2), or fluorometholone 0.1% for 1 month (OFM) or dexamethasone 0.1% for 1 month (ODM). Best-corrected visual acuity, intraocular pressure, endothelial cell density, photon count value and retinal foveal thickness were measured. Results: Mean photon count values were lower in the OBS1 and OBS2 groups compared with the ODM group during the first week. Bromfenac sodium cleared the ocular inflammation more rapidly than fluorometholone and dexamethasone. The foveal thickness was thinner in the second month and the incidence of CME was lower in the OBS1 and OBS2 groups compared with the OFM and ODM groups. Conclusion: Bromfenac sodium was more effective and safer than fluorometholone and dexamethasone as an anti-inflammatory, decreasing macular thickness and preventing CME in age-related cataract patients after cataract surgery.

Zhao JL: Prevention of blindness is still the great challenge faced by Chinese ophthalmology. Zhonghua Yan Ke Za Zhi 2009;45:769-771.
Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol 2009;3:199-210.
Colin J: The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007;67:1291-1308.
Perry HD, Donnenfeld ED: An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7:99-107.
McColgin AZ, Heier JS: Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000;11:3-6.
Oka T, Shearer T, Azuma M: Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res 2004;29:27-34.
Guex-Crosier Y: Non-steroidal anti-inflammatory drugs and ocular inflammation. Klin Monbl Augenheilkd 2001;218:305-308.
Tajika T, Isowaki A, Sakaki H: Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther 2011;27:43-49.
Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin 2006;22:1133-1140.
Kim SJ, Flach AJ, Jampol LM: Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-133.
McGhee CN, Dean S, Danesh-Meyer H: Locally administered ocular corticosteroids: benefits and risks. Drug Saf 2002;25:33-55.
Silverstein SM, Cable MG, Sadri E, Peace JH, Fong R, Chandler SP, Gow JA, Klier SM, McNamara TR: Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain. Curr Med Res Opin 2011;27:1693-1703.
Henderson BA, Gayton JL, Chandler SP, Gow JA, Klier SM, McNamara TR: Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain. Ophthalmology 2011;118:2120-2127.
Donnenfeld ED, Donnenfeld A: Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int Ophthalmol Clin 2006;46:21-40.
Flach AJ: Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11.
Flach AJ, Kraff MC, Sanders DR, Tanenbaum L: The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophthalmol 1988;106:480-483.
Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S: Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol 2009;87:300-305.
O'Brien TP: Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. Curr Med Res Opin 2005;21:1131-1137.
Heier JS, Topping TM, Baumann W, Dirks MS, Chern S: Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034-2038.
Saari KM, Nelimarkka L, Ahola V, Loftsson T, Stefansson E: Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol 2006;244:620-626.
Alio JL, Sayans JA, Chipont E: Flare-cell measurement of inflammation after uneventful cataract surgery with intraocular lens implantation. J Cataract Refract Surg 1997;23:935-939.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.